'Longeveron: More Positive Clinical Data and Imaging Biomarker Results in Alzheimer's Study'

 

• New clinical data showed that Lomecel-B™ improved cognitive function in multiple measures in a dose-response fashion
• Caregiver ratings documented improved quality of life in Lomecel-B™ treated patients
• MRI Biomarker study data showed that Lomecel-B™ countered loss of brain volume in multiple areas associated with Alzheimer’s disease, reduced brain neuroinflammation and improved cerebral blood flow
• Overall results confirmed the drug product’s therapeutic potential in the treatment of mild Alzheimer’s disease and support further development

https://www.globenewswire.com/news-release/2023/12/20/2799201/0/en/Longeveron-Announces-Additional-Positive-Clinical-Data-and-Imaging-Biomarker-Results-from-the-CLEAR-MIND-Phase-2a-Trial-of-Lomecel-B-in-the-Treatment-of-Mild-Alzheimer-s-Disease.html